TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types.

导出 OA

翻译打印收藏纠错

第一作者： Jia-Zheng,Cao

第一单位： Department of Urology, Jiangmen Central Hospital, Jiangmen, Guangdong, China.

作者： Jia-Zheng,Cao ^[1] ; Gao-Sheng,Yao ^[2] ; Fei,Liu ^[3] ; Yi-Ming,Tang ^[2] ; Peng-Ju,Li ^[2] ; Zi-Hao,Feng ^[2] ; Jun-Hang,Luo ^[2] ; Jin-Huan,Wei ^[2]

作者单位： Department of Urology, Jiangmen Central Hospital, Jiangmen, Guangdong, China. ^[1] Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China. ^[2] Department of Urology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. ^[3]

关键词 BRAF TP53 immune-checkpoint inhibitor therapies precision medicine prognosis

主题词人类(Humans);免疫疗法(Immunotherapy);突变(Mutation);肿瘤(Neoplasms);原癌基因蛋白质B-raf(Proto-Oncogene Proteins B-raf);肿瘤抑制蛋白质p53(Tumor Suppressor Protein p53)

DOI 10.18632/aging.203980

PMID 35344507

发布时间 2022-05-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交